#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Kounis syndrome is defined as acute coronary syndromes ( ACS ) induced by hypersensitivity and anaphylactic reaction .
3-1	15-21	Kounis	person|abstract[4]	new|new[4]	coref|coref|coref|coref	4-7|4-7[12_4]|4-7|4-7[12_4]
3-2	22-30	syndrome	abstract[4]	new[4]	_	_
3-3	31-33	is	_	_	_	_
3-4	34-41	defined	_	_	_	_
3-5	42-44	as	_	_	_	_
3-6	45-50	acute	_	_	_	_
3-7	51-59	coronary	person	new	coref	8-8
3-8	60-69	syndromes	_	_	_	_
3-9	70-71	(	_	_	_	_
3-10	72-75	ACS	abstract	new	coref	37-6
3-11	76-77	)	_	_	_	_
3-12	78-85	induced	_	_	_	_
3-13	86-88	by	_	_	_	_
3-14	89-105	hypersensitivity	abstract|abstract[8]	new|new[8]	coref|coref|coref|coref	21-6|21-6[117_8]|21-6|21-6[117_8]
3-15	106-109	and	abstract[8]	new[8]	_	_
3-16	110-122	anaphylactic	abstract[8]|abstract[9]	new[8]|new[9]	coref	11-1[59_9]
3-17	123-131	reaction	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-18	132-133	.	_	_	_	_

#Text=Several causes are reported to induce Kounis syndrome , such as medicines , environmental exposures , bee stings , and asthma ( Table 2 ) .
4-1	134-141	Several	abstract[10]	new[10]	_	_
4-2	142-148	causes	abstract[10]	new[10]	_	_
4-3	149-152	are	_	_	_	_
4-4	153-161	reported	_	_	_	_
4-5	162-164	to	_	_	_	_
4-6	165-171	induce	_	_	_	_
4-7	172-178	Kounis	person|abstract[12]	giv|giv[12]	coref|coref|coref|coref	5-14|5-14[23_12]|5-14|5-14[23_12]
4-8	179-187	syndrome	abstract[12]	giv[12]	_	_
4-9	188-189	,	abstract[12]	giv[12]	_	_
4-10	190-194	such	abstract[12]	giv[12]	_	_
4-11	195-197	as	abstract[12]	giv[12]	_	_
4-12	198-207	medicines	abstract[12]|substance	giv[12]|new	_	_
4-13	208-209	,	abstract[12]	giv[12]	_	_
4-14	210-223	environmental	abstract[12]|abstract[14]	giv[12]|new[14]	_	_
4-15	224-233	exposures	abstract[12]|abstract[14]	giv[12]|new[14]	_	_
4-16	234-235	,	abstract[12]	giv[12]	_	_
4-17	236-239	bee	abstract[12]|animal|abstract[16]	giv[12]|new|new[16]	_	_
4-18	240-246	stings	abstract[12]|abstract[16]	giv[12]|new[16]	_	_
4-19	247-248	,	abstract[12]	giv[12]	_	_
4-20	249-252	and	abstract[12]	giv[12]	_	_
4-21	253-259	asthma	abstract[12]|abstract	giv[12]|new	_	_
4-22	260-261	(	_	_	_	_
4-23	262-267	Table	abstract[18]	new[18]	_	_
4-24	268-269	2	abstract[18]	new[18]	_	_
4-25	270-271	)	_	_	_	_
4-26	272-273	.	_	_	_	_

#Text=Ayhan Akoz et al. conducted a prospective study and found the incidence of Kounis syndrome in all admissions to be 19.4/100,000 .
5-1	274-279	Ayhan	person[19]	new[19]	_	_
5-2	280-284	Akoz	person[19]	new[19]	_	_
5-3	285-287	et	_	_	_	_
5-4	288-291	al.	_	_	_	_
5-5	292-301	conducted	_	_	_	_
5-6	302-303	a	abstract[20]	new[20]	coref	13-7[77_20]
5-7	304-315	prospective	abstract[20]	new[20]	_	_
5-8	316-321	study	abstract[20]	new[20]	_	_
5-9	322-325	and	_	_	_	_
5-10	326-331	found	_	_	_	_
5-11	332-335	the	abstract[21]	new[21]	_	_
5-12	336-345	incidence	abstract[21]	new[21]	_	_
5-13	346-348	of	abstract[21]	new[21]	_	_
5-14	349-355	Kounis	abstract[21]|person|abstract[23]	new[21]|giv|giv[23]	coref|coref|coref|coref	7-9|7-9[33_23]|7-9|7-9[33_23]
5-15	356-364	syndrome	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
5-16	365-367	in	abstract[21]|abstract[23]	new[21]|giv[23]	_	_
5-17	368-371	all	abstract[21]|abstract[23]|event[24]	new[21]|giv[23]|new[24]	_	_
5-18	372-382	admissions	abstract[21]|abstract[23]|event[24]	new[21]|giv[23]|new[24]	_	_
5-19	383-385	to	_	_	_	_
5-20	386-388	be	_	_	_	_
5-21	389-401	19.4/100,000	quantity	new	_	_
5-22	402-403	.	_	_	_	_

#Text=The most common etiology reported was the use of medications , accounting for about 81 % .
6-1	404-407	The	abstract[26]	new[26]	_	_
6-2	408-412	most	abstract[26]	new[26]	_	_
6-3	413-419	common	abstract[26]	new[26]	_	_
6-4	420-428	etiology	abstract[26]	new[26]	_	_
6-5	429-437	reported	_	_	_	_
6-6	438-441	was	_	_	_	_
6-7	442-445	the	abstract[27]	new[27]	_	_
6-8	446-449	use	abstract[27]	new[27]	_	_
6-9	450-452	of	abstract[27]	new[27]	_	_
6-10	453-464	medications	abstract[27]|substance	new[27]|new	_	_
6-11	465-466	,	_	_	_	_
6-12	467-477	accounting	_	_	_	_
6-13	478-481	for	_	_	_	_
6-14	482-487	about	quantity[29]	new[29]	_	_
6-15	488-490	81	quantity[29]	new[29]	_	_
6-16	491-492	%	quantity[29]	new[29]	_	_
6-17	493-494	.	_	_	_	_

#Text=In the current concept , three variants of Kounis syndrome have been described .
7-1	495-497	In	_	_	_	_
7-2	498-501	the	abstract[30]	new[30]	coref	20-2[109_30]
7-3	502-509	current	abstract[30]	new[30]	_	_
7-4	510-517	concept	abstract[30]	new[30]	_	_
7-5	518-519	,	_	_	_	_
7-6	520-525	three	abstract[31]	new[31]	_	_
7-7	526-534	variants	abstract[31]	new[31]	_	_
7-8	535-537	of	abstract[31]	new[31]	_	_
7-9	538-544	Kounis	abstract[31]|person|abstract[33]	new[31]|giv|giv[33]	coref|coref|coref|coref	9-5|9-5[47_33]|9-5|9-5[47_33]
7-10	545-553	syndrome	abstract[31]|abstract[33]	new[31]|giv[33]	_	_
7-11	554-558	have	_	_	_	_
7-12	559-563	been	_	_	_	_
7-13	564-573	described	_	_	_	_
7-14	574-575	.	_	_	_	_

#Text=Type I variant is characterized by allergy-related coronary spasm without coronary lesions or risk factors .
8-1	576-580	Type	abstract	new	coref	9-3
8-2	581-582	I	person|object[36]	acc|new[36]	coref|coref	10-3[56_36]|10-3[56_36]
8-3	583-590	variant	object[36]	new[36]	_	_
8-4	591-593	is	_	_	_	_
8-5	594-607	characterized	_	_	_	_
8-6	608-610	by	_	_	_	_
8-7	611-626	allergy-related	abstract[38]	new[38]	coref	9-25[54_38]
8-8	627-635	coronary	person|abstract[38]	giv|new[38]	coref	8-11
8-9	636-641	spasm	abstract[38]	new[38]	_	_
8-10	642-649	without	_	_	_	_
8-11	650-658	coronary	object|abstract[40]	giv|new[40]	coref|coref	9-25|9-25
8-12	659-666	lesions	abstract[40]	new[40]	_	_
8-13	667-669	or	_	_	_	_
8-14	670-674	risk	abstract|abstract[42]	new|new[42]	coref|coref	24-1[143_42]|24-1[143_42]
8-15	675-682	factors	abstract[42]	new[42]	_	_
8-16	683-684	.	_	_	_	_

#Text=Patients with type I Kounis syndrome present electrocardiographic change with or without cardiac enzymes elevation due to the acute release of inflammatory mediators inducing coronary spasm .
9-1	685-693	Patients	person[43]	new[43]	coref	12-7[69_43]
9-2	694-698	with	person[43]	new[43]	_	_
9-3	699-703	type	person[43]|abstract	new[43]|giv	coref	10-1[55_0]
9-4	704-705	I	person[43]|person	new[43]|acc	_	_
9-5	706-712	Kounis	person[43]|person|abstract[47]	new[43]|giv|giv[47]	coref|coref|coref|coref	16-11|16-11[105_47]|16-11|16-11[105_47]
9-6	713-721	syndrome	person[43]|abstract[47]	new[43]|giv[47]	_	_
9-7	722-729	present	_	_	_	_
9-8	730-750	electrocardiographic	abstract[48]	new[48]	_	_
9-9	751-757	change	abstract[48]	new[48]	_	_
9-10	758-762	with	_	_	_	_
9-11	763-765	or	_	_	_	_
9-12	766-773	without	_	_	_	_
9-13	774-781	cardiac	abstract[50]	new[50]	_	_
9-14	782-789	enzymes	abstract|abstract[50]	new|new[50]	_	_
9-15	790-799	elevation	abstract[50]	new[50]	_	_
9-16	800-803	due	abstract[50]	new[50]	_	_
9-17	804-806	to	_	_	_	_
9-18	807-810	the	event[51]	new[51]	_	_
9-19	811-816	acute	event[51]	new[51]	_	_
9-20	817-824	release	event[51]	new[51]	_	_
9-21	825-827	of	event[51]	new[51]	_	_
9-22	828-840	inflammatory	event[51]|person[52]	new[51]|new[52]	coref	11-10[61_52]
9-23	841-850	mediators	event[51]|person[52]	new[51]|new[52]	_	_
9-24	851-859	inducing	_	_	_	_
9-25	860-868	coronary	person|abstract[54]	giv|giv[54]	coref|coref	12-10|12-10
9-26	869-874	spasm	abstract[54]	giv[54]	_	_
9-27	875-876	.	_	_	_	_

#Text=The type II variant includes pre-existing atheromatous disease .
10-1	877-880	The	abstract[55]	giv[55]	coref	12-1[68_55]
10-2	881-885	type	abstract[55]	giv[55]	_	_
10-3	886-888	II	abstract[55]|object[56]	giv[55]|giv[56]	_	_
10-4	889-896	variant	abstract[55]|object[56]	giv[55]|giv[56]	_	_
10-5	897-905	includes	_	_	_	_
10-6	906-918	pre-existing	abstract[58]	new[58]	coref	12-9[71_58]
10-7	919-931	atheromatous	object|abstract[58]	new|new[58]	_	_
10-8	932-939	disease	abstract[58]	new[58]	_	_
10-9	940-941	.	_	_	_	_

#Text=An acute allergic reaction leading to the release of inflammatory mediators induces plaque erosion or rupture , which causes acute myocardial infarction .
11-1	942-944	An	abstract[59]	giv[59]	coref	23-14[134_59]
11-2	945-950	acute	abstract[59]	giv[59]	_	_
11-3	951-959	allergic	abstract[59]	giv[59]	_	_
11-4	960-968	reaction	abstract[59]	giv[59]	_	_
11-5	969-976	leading	_	_	_	_
11-6	977-979	to	_	_	_	_
11-7	980-983	the	event[60]	new[60]	_	_
11-8	984-991	release	event[60]	new[60]	_	_
11-9	992-994	of	event[60]	new[60]	_	_
11-10	995-1007	inflammatory	event[60]|person[61]	new[60]|giv[61]	coref	21-12[119_61]
11-11	1008-1017	mediators	event[60]|person[61]	new[60]|giv[61]	_	_
11-12	1018-1025	induces	_	_	_	_
11-13	1026-1032	plaque	object|abstract[63]|abstract[64]	new|new[63]|new[64]	coref|coref|coref|coref|coref|coref|coref|coref|coref	25-5|25-5[151_63]|25-5[152_64]|25-5|25-5[151_63]|25-5[152_64]|25-5|25-5[151_63]|25-5[152_64]
11-14	1033-1040	erosion	abstract[63]|abstract[64]	new[63]|new[64]	_	_
11-15	1041-1043	or	abstract[64]	new[64]	_	_
11-16	1044-1051	rupture	abstract[64]|event	new[64]|new	coref	25-8
11-17	1052-1053	,	_	_	_	_
11-18	1054-1059	which	_	_	_	_
11-19	1060-1066	causes	_	_	_	_
11-20	1067-1072	acute	event[67]	new[67]	_	_
11-21	1073-1083	myocardial	object|event[67]	new|new[67]	_	_
11-22	1084-1094	infarction	event[67]	new[67]	_	_
11-23	1095-1096	.	_	_	_	_

#Text=Type III has been defined in patients with pre-existing coronary disease and coronary artery stent thrombosis .
12-1	1097-1101	Type	abstract[68]	giv[68]	_	_
12-2	1102-1105	III	abstract[68]	giv[68]	_	_
12-3	1106-1109	has	_	_	_	_
12-4	1110-1114	been	_	_	_	_
12-5	1115-1122	defined	_	_	_	_
12-6	1123-1125	in	_	_	_	_
12-7	1126-1134	patients	person[69]	giv[69]	coref	13-20[83_69]
12-8	1135-1139	with	person[69]	giv[69]	_	_
12-9	1140-1152	pre-existing	person[69]|abstract[71]	giv[69]|giv[71]	_	_
12-10	1153-1161	coronary	person[69]|person|abstract[71]	giv[69]|giv|giv[71]	coref	12-13
12-11	1162-1169	disease	person[69]|abstract[71]	giv[69]|giv[71]	_	_
12-12	1170-1173	and	person[69]	giv[69]	_	_
12-13	1174-1182	coronary	person[69]|person|abstract[75]	giv[69]|giv|new[75]	coref|coref|coref|coref	13-18[82_75]|26-8|13-18[82_75]|26-8
12-14	1183-1189	artery	person[69]|object|abstract[75]	giv[69]|new|new[75]	_	_
12-15	1190-1195	stent	person[69]|abstract|abstract[75]	giv[69]|new|new[75]	coref	13-13[80_0]
12-16	1196-1206	thrombosis	person[69]|abstract[75]	giv[69]|new[75]	_	_
12-17	1207-1208	.	_	_	_	_

#Text=In the Jack P. Chen et al. study , the pathology of drug-eluting stent ( DES ) thrombosis in these patients presented with eosinophils and mast cell infiltration in Giemsa and hematoxylin – eosin staining .
13-1	1209-1211	In	_	_	_	_
13-2	1212-1215	the	person[76]|abstract[78]	new[76]|new[78]	_	_
13-3	1216-1220	Jack	person[76]|abstract[78]	new[76]|new[78]	_	_
13-4	1221-1223	P.	person[76]|abstract[78]	new[76]|new[78]	_	_
13-5	1224-1228	Chen	person[76]|abstract[78]	new[76]|new[78]	_	_
13-6	1229-1231	et	abstract[78]	new[78]	_	_
13-7	1232-1235	al.	abstract[77]|abstract[78]	giv[77]|new[78]	coref	14-2[92_77]
13-8	1236-1241	study	abstract[77]|abstract[78]	giv[77]|new[78]	_	_
13-9	1242-1243	,	abstract[78]	new[78]	_	_
13-10	1244-1247	the	abstract[78]	new[78]	_	_
13-11	1248-1257	pathology	abstract[78]	new[78]	_	_
13-12	1258-1260	of	abstract[78]	new[78]	_	_
13-13	1261-1273	drug-eluting	abstract[78]|abstract|abstract[80]	new[78]|new|giv[80]	appos|appos	13-16[0_80]|13-16[0_80]
13-14	1274-1279	stent	abstract[78]|abstract[80]	new[78]|giv[80]	_	_
13-15	1280-1281	(	_	_	_	_
13-16	1282-1285	DES	abstract	giv	coref	14-13
13-17	1286-1287	)	_	_	_	_
13-18	1288-1298	thrombosis	abstract[82]	giv[82]	coref	14-12[95_82]
13-19	1299-1301	in	abstract[82]	giv[82]	_	_
13-20	1302-1307	these	abstract[82]|person[83]	giv[82]|giv[83]	coref	32-6[181_83]
13-21	1308-1316	patients	abstract[82]|person[83]	giv[82]|giv[83]	_	_
13-22	1317-1326	presented	_	_	_	_
13-23	1327-1331	with	_	_	_	_
13-24	1332-1343	eosinophils	abstract	new	_	_
13-25	1344-1347	and	_	_	_	_
13-26	1348-1352	mast	abstract[86]	new[86]	_	_
13-27	1353-1357	cell	object|abstract[86]	new|new[86]	coref	20-11[112_0]
13-28	1358-1370	infiltration	abstract[86]	new[86]	_	_
13-29	1371-1373	in	abstract[86]	new[86]	_	_
13-30	1374-1380	Giemsa	abstract[86]|person	new[86]|new	_	_
13-31	1381-1384	and	abstract[86]	new[86]	_	_
13-32	1385-1396	hematoxylin	abstract[86]|object	new[86]|new	_	_
13-33	1397-1398	–	_	_	_	_
13-34	1399-1404	eosin	person|abstract[90]	new|new[90]	_	_
13-35	1405-1413	staining	abstract[90]	new[90]	_	_
13-36	1414-1415	.	_	_	_	_

#Text=In the Stéphane Cook et al. study , the association with late DES thrombosis and local inflammation in histopathology was reported .
14-1	1416-1418	In	_	_	_	_
14-2	1419-1422	the	abstract[92]|abstract[93]	giv[92]|new[93]	_	_
14-3	1423-1431	Stéphane	person[91]|abstract[92]|abstract[93]	new[91]|giv[92]|new[93]	_	_
14-4	1432-1436	Cook	person[91]|abstract[92]|abstract[93]	new[91]|giv[92]|new[93]	_	_
14-5	1437-1439	et	abstract[92]|abstract[93]	giv[92]|new[93]	_	_
14-6	1440-1443	al.	abstract[92]|abstract[93]	giv[92]|new[93]	_	_
14-7	1444-1449	study	abstract[92]|abstract[93]	giv[92]|new[93]	_	_
14-8	1450-1451	,	abstract[93]	new[93]	_	_
14-9	1452-1455	the	abstract[93]	new[93]	_	_
14-10	1456-1467	association	abstract[93]	new[93]	_	_
14-11	1468-1472	with	abstract[93]	new[93]	_	_
14-12	1473-1477	late	abstract[93]|abstract[95]	new[93]|giv[95]	coref	16-1[103_95]
14-13	1478-1481	DES	abstract[93]|abstract|abstract[95]	new[93]|giv|giv[95]	coref	16-3
14-14	1482-1492	thrombosis	abstract[93]|abstract[95]	new[93]|giv[95]	_	_
14-15	1493-1496	and	abstract[93]	new[93]	_	_
14-16	1497-1502	local	abstract[93]|abstract[96]	new[93]|new[96]	_	_
14-17	1503-1515	inflammation	abstract[93]|abstract[96]	new[93]|new[96]	_	_
14-18	1516-1518	in	abstract[93]|abstract[96]	new[93]|new[96]	_	_
14-19	1519-1533	histopathology	abstract[93]|abstract[96]|abstract	new[93]|new[96]|new	_	_
14-20	1534-1537	was	_	_	_	_
14-21	1538-1546	reported	_	_	_	_
14-22	1547-1548	.	_	_	_	_

#Text=In intravascular ultrasound analysis , vessel remodeling was also confirmed .
15-1	1549-1551	In	_	_	_	_
15-2	1552-1565	intravascular	abstract[99]	new[99]	_	_
15-3	1566-1576	ultrasound	abstract|abstract[99]	new|new[99]	_	_
15-4	1577-1585	analysis	abstract[99]	new[99]	_	_
15-5	1586-1587	,	_	_	_	_
15-6	1588-1594	vessel	object|abstract[101]	new|new[101]	_	_
15-7	1595-1605	remodeling	abstract[101]	new[101]	_	_
15-8	1606-1609	was	_	_	_	_
15-9	1610-1614	also	_	_	_	_
15-10	1615-1624	confirmed	_	_	_	_
15-11	1625-1626	.	_	_	_	_

#Text=Very late stent thrombosis is recognized as a feature of Kounis syndrome (
16-1	1627-1631	Very	abstract[103]	giv[103]	_	_
16-2	1632-1636	late	abstract[103]	giv[103]	_	_
16-3	1637-1642	stent	abstract|abstract[103]	giv|giv[103]	_	_
16-4	1643-1653	thrombosis	abstract[103]	giv[103]	_	_
16-5	1654-1656	is	_	_	_	_
16-6	1657-1667	recognized	_	_	_	_
16-7	1668-1670	as	_	_	_	_
16-8	1671-1672	a	_	_	_	_
16-9	1673-1680	feature	_	_	_	_
16-10	1681-1683	of	_	_	_	_
16-11	1684-1690	Kounis	person|abstract[105]	giv|giv[105]	coref|coref|coref|coref	20-6|20-6[111_105]|20-6|20-6[111_105]
16-12	1691-1699	syndrome	abstract[105]	giv[105]	_	_
16-13	1700-1701	(	_	_	_	_

#Text=Figure 5
17-1	1702-1708	Figure	abstract[106]	new[106]	coref	29-1[176_106]
17-2	1709-1710	5	abstract[106]	new[106]	_	_

#Text=) .
18-1	1711-1712	)	_	_	_	_
18-2	1713-1714	.	_	_	_	_

#Text=The detail pathophysiological mechanisms remain elusive .
19-1	1715-1718	The	abstract[107]	new[107]	_	_
19-2	1719-1725	detail	abstract[107]	new[107]	_	_
19-3	1726-1744	pathophysiological	abstract[108]	new[108]	_	_
19-4	1745-1755	mechanisms	abstract[108]	new[108]	_	_
19-5	1756-1762	remain	_	_	_	_
19-6	1763-1770	elusive	_	_	_	_
19-7	1771-1772	.	_	_	_	_

#Text=In the current concept , Kounis syndrome is related to inflammatory cell and mast cell-associated disorders .
20-1	1773-1775	In	_	_	_	_
20-2	1776-1779	the	abstract[109]	giv[109]	coref	39-2[238_109]
20-3	1780-1787	current	abstract[109]	giv[109]	_	_
20-4	1788-1795	concept	abstract[109]	giv[109]	_	_
20-5	1796-1797	,	_	_	_	_
20-6	1798-1804	Kounis	person|abstract[111]	giv|giv[111]	coref|coref|coref|coref	22-10|22-10[124_111]|22-10|22-10[124_111]
20-7	1805-1813	syndrome	abstract[111]	giv[111]	_	_
20-8	1814-1816	is	_	_	_	_
20-9	1817-1824	related	_	_	_	_
20-10	1825-1827	to	_	_	_	_
20-11	1828-1840	inflammatory	object[112]	giv[112]	coref	21-3[0_112]
20-12	1841-1845	cell	object[112]	giv[112]	_	_
20-13	1846-1849	and	_	_	_	_
20-14	1850-1854	mast	abstract[113]	new[113]	coref	33-15[191_113]
20-15	1855-1870	cell-associated	abstract[113]	new[113]	_	_
20-16	1871-1880	disorders	abstract[113]	new[113]	_	_
20-17	1881-1882	.	_	_	_	_

#Text=Local inflammatory cell interactions induce hypersensitivity and anaphylactic results by releasing inflammatory mediators after activation .
21-1	1883-1888	Local	abstract[115]	new[115]	_	_
21-2	1889-1901	inflammatory	abstract[115]	new[115]	_	_
21-3	1902-1906	cell	object|abstract[115]	giv|new[115]	_	_
21-4	1907-1919	interactions	abstract[115]	new[115]	_	_
21-5	1920-1926	induce	_	_	_	_
21-6	1927-1943	hypersensitivity	abstract|abstract[117]	giv|giv[117]	_	_
21-7	1944-1947	and	abstract[117]	giv[117]	_	_
21-8	1948-1960	anaphylactic	abstract[117]|abstract[118]	giv[117]|new[118]	coref	35-1[217_118]
21-9	1961-1968	results	abstract[117]|abstract[118]	giv[117]|new[118]	_	_
21-10	1969-1971	by	_	_	_	_
21-11	1972-1981	releasing	_	_	_	_
21-12	1982-1994	inflammatory	person[119]	giv[119]	coref	23-10[133_119]
21-13	1995-2004	mediators	person[119]	giv[119]	_	_
21-14	2005-2010	after	_	_	_	_
21-15	2011-2021	activation	event	new	_	_
21-16	2022-2023	.	_	_	_	_

#Text=In the Nicholas G. Kounis et al. summary , Kounis syndrome is a complex multisystem disease accompanied by allergy – hypersensitivity – anaphylaxis .
22-1	2024-2026	In	_	_	_	_
22-2	2027-2030	the	person[121]	new[121]	_	_
22-3	2031-2039	Nicholas	person[121]	new[121]	_	_
22-4	2040-2042	G.	person[121]	new[121]	_	_
22-5	2043-2049	Kounis	person[121]	new[121]	_	_
22-6	2050-2052	et	_	_	_	_
22-7	2053-2056	al.	abstract[122]	new[122]	_	_
22-8	2057-2064	summary	abstract[122]	new[122]	_	_
22-9	2065-2066	,	_	_	_	_
22-10	2067-2073	Kounis	person|abstract[124]	giv|giv[124]	coref|coref|coref|coref	22-13[126_124]|27-4|22-13[126_124]|27-4
22-11	2074-2082	syndrome	abstract[124]	giv[124]	_	_
22-12	2083-2085	is	_	_	_	_
22-13	2086-2087	a	abstract[126]	giv[126]	coref	27-4[163_126]
22-14	2088-2095	complex	abstract[126]	giv[126]	_	_
22-15	2096-2107	multisystem	object|abstract[126]	new|giv[126]	_	_
22-16	2108-2115	disease	abstract[126]	giv[126]	_	_
22-17	2116-2127	accompanied	_	_	_	_
22-18	2128-2130	by	_	_	_	_
22-19	2131-2138	allergy	abstract	new	appos	22-21
22-20	2139-2140	–	_	_	_	_
22-21	2141-2157	hypersensitivity	abstract	giv	coref	23-2
22-22	2158-2159	–	_	_	_	_
22-23	2160-2171	anaphylaxis	abstract	new	_	_
22-24	2172-2173	.	_	_	_	_

#Text=During hypersensitivity , the mast cells and lymphocytes release inflammatory mediators , promoting an allergic reaction via a high serum level of histamine , proteases , arachidonic acid products , and chemokines .
23-1	2174-2180	During	_	_	_	_
23-2	2181-2197	hypersensitivity	abstract	giv	coref	39-14
23-3	2198-2199	,	_	_	_	_
23-4	2200-2203	the	object[131]	new[131]	_	_
23-5	2204-2208	mast	object[131]	new[131]	_	_
23-6	2209-2214	cells	object[131]	new[131]	_	_
23-7	2215-2218	and	_	_	_	_
23-8	2219-2230	lymphocytes	organization	new	_	_
23-9	2231-2238	release	_	_	_	_
23-10	2239-2251	inflammatory	person[133]	giv[133]	coref	26-1[157_133]
23-11	2252-2261	mediators	person[133]	giv[133]	_	_
23-12	2262-2263	,	_	_	_	_
23-13	2264-2273	promoting	_	_	_	_
23-14	2274-2276	an	abstract[134]	giv[134]	coref	28-13[175_134]
23-15	2277-2285	allergic	abstract[134]	giv[134]	_	_
23-16	2286-2294	reaction	abstract[134]	giv[134]	_	_
23-17	2295-2298	via	abstract[134]	giv[134]	_	_
23-18	2299-2300	a	abstract[134]|abstract[136]	giv[134]|new[136]	_	_
23-19	2301-2305	high	abstract[134]|abstract[136]	giv[134]|new[136]	_	_
23-20	2306-2311	serum	abstract[134]|object|abstract[136]	giv[134]|new|new[136]	coref	28-2
23-21	2312-2317	level	abstract[134]|abstract[136]	giv[134]|new[136]	_	_
23-22	2318-2320	of	abstract[134]|abstract[136]	giv[134]|new[136]	_	_
23-23	2321-2330	histamine	abstract[134]|abstract[136]|substance	giv[134]|new[136]|new	coref	28-7
23-24	2331-2332	,	abstract[134]|abstract[136]	giv[134]|new[136]	_	_
23-25	2333-2342	proteases	abstract[134]|abstract[136]|substance	giv[134]|new[136]|new	coref	25-1[149_0]
23-26	2343-2344	,	abstract[134]|abstract[136]	giv[134]|new[136]	_	_
23-27	2345-2356	arachidonic	abstract[134]|abstract[136]|abstract|substance[141]	giv[134]|new[136]|new|new[141]	coref|coref	41-14|41-14
23-28	2357-2361	acid	abstract[134]|abstract[136]|substance|substance[141]	giv[134]|new[136]|new|new[141]	coref	33-44[201_0]
23-29	2362-2370	products	abstract[134]|abstract[136]|substance[141]	giv[134]|new[136]|new[141]	_	_
23-30	2371-2372	,	abstract[134]|abstract[136]	giv[134]|new[136]	_	_
23-31	2373-2376	and	abstract[134]|abstract[136]	giv[134]|new[136]	_	_
23-32	2377-2387	chemokines	abstract[134]|abstract[136]|substance	giv[134]|new[136]|new	_	_
23-33	2388-2389	.	_	_	_	_

#Text=These factors cause platelet aggregating and tissue factor expression .
24-1	2390-2395	These	abstract[143]	giv[143]	_	_
24-2	2396-2403	factors	abstract[143]	giv[143]	_	_
24-3	2404-2409	cause	_	_	_	_
24-4	2410-2418	platelet	object|abstract[145]	new|new[145]	_	_
24-5	2419-2430	aggregating	abstract[145]	new[145]	_	_
24-6	2431-2434	and	_	_	_	_
24-7	2435-2441	tissue	object|abstract[147]|abstract[148]	new|new[147]|new[148]	_	_
24-8	2442-2448	factor	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-9	2449-2459	expression	abstract[148]	new[148]	_	_
24-10	2460-2461	.	_	_	_	_

#Text=The proteases also induce plaque erosion and rupture by activating matrix metalloproteinase ( MMP ) .
25-1	2462-2465	The	substance[149]	giv[149]	_	_
25-2	2466-2475	proteases	substance[149]	giv[149]	_	_
25-3	2476-2480	also	_	_	_	_
25-4	2481-2487	induce	_	_	_	_
25-5	2488-2494	plaque	object|event[151]|abstract[152]	giv|giv[151]|giv[152]	_	_
25-6	2495-2502	erosion	event[151]|abstract[152]	giv[151]|giv[152]	_	_
25-7	2503-2506	and	abstract[152]	giv[152]	_	_
25-8	2507-2514	rupture	abstract[152]|event	giv[152]|giv	_	_
25-9	2515-2517	by	_	_	_	_
25-10	2518-2528	activating	_	_	_	_
25-11	2529-2535	matrix	abstract|substance[155]	new|new[155]	_	_
25-12	2536-2553	metalloproteinase	substance[155]	new[155]	_	_
25-13	2554-2555	(	_	_	_	_
25-14	2556-2559	MMP	object	new	_	_
25-15	2560-2561	)	_	_	_	_
25-16	2562-2563	.	_	_	_	_

#Text=The downstream mediators induce vasoconstriction and worsen coronary vasospasm .
26-1	2564-2567	The	person[157]	giv[157]	_	_
26-2	2568-2578	downstream	person[157]	giv[157]	_	_
26-3	2579-2588	mediators	person[157]	giv[157]	_	_
26-4	2589-2595	induce	_	_	_	_
26-5	2596-2612	vasoconstriction	event	new	_	_
26-6	2613-2616	and	_	_	_	_
26-7	2617-2623	worsen	_	_	_	_
26-8	2624-2632	coronary	person|abstract[160]	giv|new[160]	coref|coref|coref|coref	33-3|42-8[266_160]|33-3|42-8[266_160]
26-9	2633-2642	vasospasm	abstract[160]	new[160]	_	_
26-10	2643-2644	.	_	_	_	_

#Text=The diagnosis of Kounis syndrome is based on clinical symptoms and cardiac surveys , including cardiac enzyme , electrocardiographic , echocardiographic , and angiography .
27-1	2645-2648	The	abstract[161]	new[161]	_	_
27-2	2649-2658	diagnosis	abstract[161]	new[161]	_	_
27-3	2659-2661	of	abstract[161]	new[161]	_	_
27-4	2662-2668	Kounis	abstract[161]|person|abstract[163]	new[161]|giv|giv[163]	coref|coref|coref|coref	32-14|32-14[183_163]|32-14|32-14[183_163]
27-5	2669-2677	syndrome	abstract[161]|abstract[163]	new[161]|giv[163]	_	_
27-6	2678-2680	is	_	_	_	_
27-7	2681-2686	based	_	_	_	_
27-8	2687-2689	on	_	_	_	_
27-9	2690-2698	clinical	abstract[164]	new[164]	_	_
27-10	2699-2707	symptoms	abstract[164]	new[164]	_	_
27-11	2708-2711	and	_	_	_	_
27-12	2712-2719	cardiac	abstract|abstract[166]	new|new[166]	coref|coref	27-16|27-16
27-13	2720-2727	surveys	abstract[166]	new[166]	_	_
27-14	2728-2729	,	abstract[166]	new[166]	_	_
27-15	2730-2739	including	abstract[166]	new[166]	_	_
27-16	2740-2747	cardiac	abstract[166]|abstract|object[168]	new[166]|giv|new[168]	coref|coref	32-3|32-3
27-17	2748-2754	enzyme	abstract[166]|object[168]	new[166]|new[168]	_	_
27-18	2755-2756	,	abstract[166]	new[166]	_	_
27-19	2757-2777	electrocardiographic	abstract[166]	new[166]	_	_
27-20	2778-2779	,	abstract[166]	new[166]	_	_
27-21	2780-2797	echocardiographic	abstract[166]	new[166]	_	_
27-22	2798-2799	,	abstract[166]	new[166]	_	_
27-23	2800-2803	and	abstract[166]	new[166]	_	_
27-24	2804-2815	angiography	abstract[166]|abstract	new[166]|new	coref	33-3[187_0]
27-25	2816-2817	.	_	_	_	_

#Text=The serum level of tryptase and histamine can provide more information about the allergic reaction (
28-1	2818-2821	The	abstract[171]	new[171]	_	_
28-2	2822-2827	serum	object|abstract[171]	giv|new[171]	_	_
28-3	2828-2833	level	abstract[171]	new[171]	_	_
28-4	2834-2836	of	abstract[171]	new[171]	_	_
28-5	2837-2845	tryptase	abstract[171]|substance	new[171]|new	_	_
28-6	2846-2849	and	abstract[171]	new[171]	_	_
28-7	2850-2859	histamine	abstract[171]|substance	new[171]|giv	_	_
28-8	2860-2863	can	_	_	_	_
28-9	2864-2871	provide	_	_	_	_
28-10	2872-2876	more	abstract[174]	new[174]	coref	33-7[188_174]
28-11	2877-2888	information	abstract[174]	new[174]	_	_
28-12	2889-2894	about	abstract[174]	new[174]	_	_
28-13	2895-2898	the	abstract[174]|abstract[175]	new[174]|giv[175]	coref	32-8[0_175]
28-14	2899-2907	allergic	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
28-15	2908-2916	reaction	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
28-16	2917-2918	(	_	_	_	_

#Text=Figure 5
29-1	2919-2925	Figure	abstract[176]	giv[176]	coref	53-1[326_176]
29-2	2926-2927	5	abstract[176]	giv[176]	_	_

#Text=) .
30-1	2928-2929	)	_	_	_	_
30-2	2930-2931	.	_	_	_	_

#Text=Tajda Keber et al.
31-1	2932-2937	Tajda	person[177]	new[177]	_	_
31-2	2938-2943	Keber	person[177]	new[177]	_	_
31-3	2944-2946	et	_	_	_	_
31-4	2947-2950	al.	_	_	_	_

#Text=suggested measuring cardiac enzymes in acute allergic reaction patients as necessary to diagnose Kounis syndrome promptly and manage cardiac injury early and appropriately .
32-1	2951-2960	suggested	_	_	_	_
32-2	2961-2970	measuring	_	_	_	_
32-3	2971-2978	cardiac	abstract|abstract[179]	giv|new[179]	_	_
32-4	2979-2986	enzymes	abstract[179]	new[179]	_	_
32-5	2987-2989	in	abstract[179]	new[179]	_	_
32-6	2990-2995	acute	abstract[179]|person[181]	new[179]|giv[181]	coref	33-19[195_181]
32-7	2996-3004	allergic	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-8	3005-3013	reaction	abstract[179]|abstract|person[181]	new[179]|giv|giv[181]	coref	37-23[235_0]
32-9	3014-3022	patients	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-10	3023-3025	as	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-11	3026-3035	necessary	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-12	3036-3038	to	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-13	3039-3047	diagnose	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-14	3048-3054	Kounis	abstract[179]|person[181]|person|abstract[183]	new[179]|giv[181]|giv|giv[183]	coref|coref|coref|coref	33-55[0_183]|34-12|33-55[0_183]|34-12
32-15	3055-3063	syndrome	abstract[179]|person[181]|abstract[183]	new[179]|giv[181]|giv[183]	_	_
32-16	3064-3072	promptly	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-17	3073-3076	and	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-18	3077-3083	manage	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-19	3084-3091	cardiac	abstract[179]|person[181]|event[184]	new[179]|giv[181]|new[184]	coref	36-10[226_184]
32-20	3092-3098	injury	abstract[179]|person[181]|event[184]	new[179]|giv[181]|new[184]	_	_
32-21	3099-3104	early	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-22	3105-3108	and	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-23	3109-3122	appropriately	abstract[179]|person[181]	new[179]|giv[181]	_	_
32-24	3123-3124	.	_	_	_	_

#Text=Echocardiography and coronary angiography can provide detailed information to rule out takotsubo cardiomyopathy or other cardiac disorders in cardiac wall motion abnormalities patients . Keita Goto et al. reported that thallium-201 ( Tl ) single-photon emission CT ( SPECT ) and 125I-15-(p-iodophenyl)-3-(R , S)-methylpentadecanoic acid ( BMIPP ) SPECT were conducted in a post-Kounis syndrome patient , and they revealed a local perfusion defect with decreased BMIPP uptake .
33-1	3125-3141	Echocardiography	abstract	new	_	_
33-2	3142-3145	and	_	_	_	_
33-3	3146-3154	coronary	person|abstract[187]	giv|giv[187]	coref|coref	45-12|45-12
33-4	3155-3166	angiography	abstract[187]	giv[187]	_	_
33-5	3167-3170	can	_	_	_	_
33-6	3171-3178	provide	_	_	_	_
33-7	3179-3187	detailed	abstract[188]	giv[188]	_	_
33-8	3188-3199	information	abstract[188]	giv[188]	_	_
33-9	3200-3202	to	_	_	_	_
33-10	3203-3207	rule	_	_	_	_
33-11	3208-3211	out	_	_	_	_
33-12	3212-3221	takotsubo	person|object[190]	new|new[190]	_	_
33-13	3222-3236	cardiomyopathy	object[190]	new[190]	_	_
33-14	3237-3239	or	_	_	_	_
33-15	3240-3245	other	abstract[191]	giv[191]	_	_
33-16	3246-3253	cardiac	abstract[191]	giv[191]	_	_
33-17	3254-3263	disorders	abstract[191]	giv[191]	_	_
33-18	3264-3266	in	abstract[191]	giv[191]	_	_
33-19	3267-3274	cardiac	abstract[191]|person[195]	giv[191]|giv[195]	ana	33-59[0_195]
33-20	3275-3279	wall	abstract[191]|place|person[195]	giv[191]|new|giv[195]	_	_
33-21	3280-3286	motion	abstract[191]|abstract|person[195]	giv[191]|new|giv[195]	_	_
33-22	3287-3300	abnormalities	abstract[191]|abstract|person[195]	giv[191]|new|giv[195]	_	_
33-23	3301-3309	patients	abstract[191]|person[195]	giv[191]|giv[195]	_	_
33-24	3310-3311	.	abstract[191]|person[195]	giv[191]|giv[195]	_	_
33-25	3312-3317	Keita	abstract[191]|person[195]	giv[191]|giv[195]	_	_
33-26	3318-3322	Goto	abstract[191]|person[195]	giv[191]|giv[195]	_	_
33-27	3323-3325	et	abstract[191]|person[195]	giv[191]|giv[195]	_	_
33-28	3326-3329	al.	abstract[191]|person[195]	giv[191]|giv[195]	_	_
33-29	3330-3338	reported	_	_	_	_
33-30	3339-3343	that	_	_	_	_
33-31	3344-3356	thallium-201	object[198]	new[198]	appos	33-39[0_198]
33-32	3357-3358	(	object[198]	new[198]	_	_
33-33	3359-3361	Tl	abstract|object[198]	new|new[198]	_	_
33-34	3362-3363	)	object[198]	new[198]	_	_
33-35	3364-3377	single-photon	object[198]	new[198]	_	_
33-36	3378-3386	emission	abstract|object[198]	new|new[198]	_	_
33-37	3387-3389	CT	object[198]	new[198]	_	_
33-38	3390-3391	(	_	_	_	_
33-39	3392-3397	SPECT	object	giv	coref	33-49
33-40	3398-3399	)	_	_	_	_
33-41	3400-3403	and	_	_	_	_
33-42	3404-3431	125I-15-(p-iodophenyl)-3-(R	abstract	new	_	_
33-43	3432-3433	,	_	_	_	_
33-44	3434-3456	S)-methylpentadecanoic	substance[201]	giv[201]	coref	41-15[0_201]
33-45	3457-3461	acid	substance[201]	giv[201]	_	_
33-46	3462-3463	(	_	_	_	_
33-47	3464-3469	BMIPP	object	new	coref	33-67
33-48	3470-3471	)	_	_	_	_
33-49	3472-3477	SPECT	object	giv	_	_
33-50	3478-3482	were	_	_	_	_
33-51	3483-3492	conducted	_	_	_	_
33-52	3493-3495	in	_	_	_	_
33-53	3496-3497	a	person[205]	new[205]	_	_
33-54	3498-3509	post-Kounis	person[205]	new[205]	_	_
33-55	3510-3518	syndrome	abstract|person[205]	giv|new[205]	coref	34-9[214_0]
33-56	3519-3526	patient	person[205]	new[205]	_	_
33-57	3527-3528	,	_	_	_	_
33-58	3529-3532	and	_	_	_	_
33-59	3533-3537	they	person	giv	coref	34-6[212_0]
33-60	3538-3546	revealed	_	_	_	_
33-61	3547-3548	a	abstract[208]	new[208]	coref	35-4[219_208]
33-62	3549-3554	local	abstract[208]	new[208]	_	_
33-63	3555-3564	perfusion	abstract|abstract[208]	new|new[208]	_	_
33-64	3565-3571	defect	abstract[208]	new[208]	_	_
33-65	3572-3576	with	abstract[208]	new[208]	_	_
33-66	3577-3586	decreased	abstract[208]|abstract[210]	new[208]|new[210]	_	_
33-67	3587-3592	BMIPP	abstract[208]|abstract|abstract[210]	new[208]|giv|new[210]	_	_
33-68	3593-3599	uptake	abstract[208]|abstract[210]	new[208]|new[210]	_	_
33-69	3600-3601	.	_	_	_	_

#Text=Aylin Okur et al. included 26 patients with known or suspected Kounis syndrome and conducted contrast-enhanced magnetic resonance imaging .
34-1	3602-3607	Aylin	person[211]	new[211]	_	_
34-2	3608-3612	Okur	person[211]	new[211]	_	_
34-3	3613-3615	et	_	_	_	_
34-4	3616-3619	al.	_	_	_	_
34-5	3620-3628	included	_	_	_	_
34-6	3629-3631	26	person[212]	giv[212]	coref	43-2[267_212]
34-7	3632-3640	patients	person[212]	giv[212]	_	_
34-8	3641-3645	with	person[212]	giv[212]	_	_
34-9	3646-3651	known	person[212]|abstract[214]	giv[212]|giv[214]	coref	36-13[228_214]
34-10	3652-3654	or	person[212]|abstract[214]	giv[212]|giv[214]	_	_
34-11	3655-3664	suspected	person[212]|abstract[214]	giv[212]|giv[214]	_	_
34-12	3665-3671	Kounis	person[212]|person|abstract[214]	giv[212]|giv|giv[214]	coref	36-13
34-13	3672-3680	syndrome	person[212]|abstract[214]	giv[212]|giv[214]	_	_
34-14	3681-3684	and	_	_	_	_
34-15	3685-3694	conducted	_	_	_	_
34-16	3695-3712	contrast-enhanced	abstract[216]	new[216]	_	_
34-17	3713-3721	magnetic	abstract[216]	new[216]	_	_
34-18	3722-3731	resonance	abstract|abstract[216]	new|new[216]	_	_
34-19	3732-3739	imaging	abstract[216]	new[216]	_	_
34-20	3740-3741	.	_	_	_	_

#Text=The results revealed an early-phase subendocardial contrast defect and local edema in lesion areas in T2-weighted images .
35-1	3742-3745	The	abstract[217]	giv[217]	_	_
35-2	3746-3753	results	abstract[217]	giv[217]	_	_
35-3	3754-3762	revealed	_	_	_	_
35-4	3763-3765	an	abstract[219]	giv[219]	_	_
35-5	3766-3777	early-phase	abstract[219]	giv[219]	_	_
35-6	3778-3792	subendocardial	abstract[219]	giv[219]	_	_
35-7	3793-3801	contrast	abstract|abstract[219]	new|giv[219]	_	_
35-8	3802-3808	defect	abstract[219]	giv[219]	_	_
35-9	3809-3812	and	_	_	_	_
35-10	3813-3818	local	abstract[220]	new[220]	_	_
35-11	3819-3824	edema	abstract[220]	new[220]	_	_
35-12	3825-3827	in	abstract[220]	new[220]	_	_
35-13	3828-3834	lesion	abstract[220]|abstract|place[222]	new[220]|new|new[222]	_	_
35-14	3835-3840	areas	abstract[220]|place[222]	new[220]|new[222]	_	_
35-15	3841-3843	in	abstract[220]|place[222]	new[220]|new[222]	_	_
35-16	3844-3855	T2-weighted	abstract[220]|place[222]|object[223]	new[220]|new[222]|new[223]	coref	36-1[224_223]
35-17	3856-3862	images	abstract[220]|place[222]|object[223]	new[220]|new[222]|new[223]	_	_
35-18	3863-3864	.	_	_	_	_

#Text=These newer images provide a reliable study to assess cardiac injury in Kounis syndrome .
36-1	3865-3870	These	object[224]	giv[224]	_	_
36-2	3871-3876	newer	object[224]	giv[224]	_	_
36-3	3877-3883	images	object[224]	giv[224]	_	_
36-4	3884-3891	provide	_	_	_	_
36-5	3892-3893	a	abstract[225]	new[225]	_	_
36-6	3894-3902	reliable	abstract[225]	new[225]	_	_
36-7	3903-3908	study	abstract[225]	new[225]	_	_
36-8	3909-3911	to	_	_	_	_
36-9	3912-3918	assess	_	_	_	_
36-10	3919-3926	cardiac	event[226]	giv[226]	coref	37-18[234_226]
36-11	3927-3933	injury	event[226]	giv[226]	_	_
36-12	3934-3936	in	event[226]	giv[226]	_	_
36-13	3937-3943	Kounis	event[226]|person|abstract[228]	giv[226]|giv|giv[228]	coref|coref|coref|coref	37-13|37-13[233_228]|37-13|37-13[233_228]
36-14	3944-3952	syndrome	event[226]|abstract[228]	giv[226]|giv[228]	_	_
36-15	3953-3954	.	_	_	_	_

#Text=Compared to the majority of ACS subjects , the therapeutic strategy of Kounis syndrome should focus on both the cardiac injury and allergic reaction .
37-1	3955-3963	Compared	_	_	_	_
37-2	3964-3966	to	_	_	_	_
37-3	3967-3970	the	person[230]	new[230]	_	_
37-4	3971-3979	majority	person[230]	new[230]	_	_
37-5	3980-3982	of	person[230]	new[230]	_	_
37-6	3983-3986	ACS	abstract|person[230]	giv|new[230]	coref	50-10
37-7	3987-3995	subjects	person[230]	new[230]	_	_
37-8	3996-3997	,	_	_	_	_
37-9	3998-4001	the	abstract[231]	new[231]	_	_
37-10	4002-4013	therapeutic	abstract[231]	new[231]	_	_
37-11	4014-4022	strategy	abstract[231]	new[231]	_	_
37-12	4023-4025	of	abstract[231]	new[231]	_	_
37-13	4026-4032	Kounis	abstract[231]|person|abstract[233]	new[231]|giv|giv[233]	coref|coref|coref|coref	49-12|49-12[303_233]|49-12|49-12[303_233]
37-14	4033-4041	syndrome	abstract[231]|abstract[233]	new[231]|giv[233]	_	_
37-15	4042-4048	should	_	_	_	_
37-16	4049-4054	focus	_	_	_	_
37-17	4055-4057	on	_	_	_	_
37-18	4058-4062	both	event[234]	giv[234]	coref	39-18[243_234]
37-19	4063-4066	the	event[234]	giv[234]	_	_
37-20	4067-4074	cardiac	event[234]	giv[234]	_	_
37-21	4075-4081	injury	event[234]	giv[234]	_	_
37-22	4082-4085	and	_	_	_	_
37-23	4086-4094	allergic	abstract[235]	giv[235]	coref	39-13[242_235]
37-24	4095-4103	reaction	abstract[235]	giv[235]	_	_
37-25	4104-4105	.	_	_	_	_

#Text=Sometimes , the two different conditions may require opposing treatments .
38-1	4106-4115	Sometimes	_	_	_	_
38-2	4116-4117	,	_	_	_	_
38-3	4118-4121	the	abstract[236]	new[236]	_	_
38-4	4122-4125	two	abstract[236]	new[236]	_	_
38-5	4126-4135	different	abstract[236]	new[236]	_	_
38-6	4136-4146	conditions	abstract[236]	new[236]	_	_
38-7	4147-4150	may	_	_	_	_
38-8	4151-4158	require	_	_	_	_
38-9	4159-4167	opposing	_	_	_	_
38-10	4168-4178	treatments	abstract	new	coref	49-8[301_0]
38-11	4179-4180	.	_	_	_	_

#Text=In the current concept , the administration of medicine should avoid promoting an allergy reaction and aggravating the cardiac injury .
39-1	4181-4183	In	_	_	_	_
39-2	4184-4187	the	abstract[238]	giv[238]	_	_
39-3	4188-4195	current	abstract[238]	giv[238]	_	_
39-4	4196-4203	concept	abstract[238]	giv[238]	_	_
39-5	4204-4205	,	_	_	_	_
39-6	4206-4209	the	event[239]	new[239]	_	_
39-7	4210-4224	administration	event[239]	new[239]	_	_
39-8	4225-4227	of	event[239]	new[239]	_	_
39-9	4228-4236	medicine	event[239]|substance	new[239]|new	_	_
39-10	4237-4243	should	_	_	_	_
39-11	4244-4249	avoid	_	_	_	_
39-12	4250-4259	promoting	_	_	_	_
39-13	4260-4262	an	abstract[242]	giv[242]	coref	40-26[253_242]
39-14	4263-4270	allergy	abstract|abstract[242]	giv|giv[242]	_	_
39-15	4271-4279	reaction	abstract[242]	giv[242]	_	_
39-16	4280-4283	and	_	_	_	_
39-17	4284-4295	aggravating	_	_	_	_
39-18	4296-4299	the	event[243]	giv[243]	_	_
39-19	4300-4307	cardiac	event[243]	giv[243]	_	_
39-20	4308-4314	injury	event[243]	giv[243]	_	_
39-21	4315-4316	.	_	_	_	_

#Text=Intravenous corticosteroids ( hydrocortisone : 1 – 2 mg/kg/day ) and antihistamine agents ( diphenhydramine : 1 – 2 mg/kg ) are useful to control the allergic reaction .
40-1	4317-4328	Intravenous	object[244]	new[244]	coref	55-3[0_244]
40-2	4329-4344	corticosteroids	object[244]	new[244]	_	_
40-3	4345-4346	(	_	_	_	_
40-4	4347-4361	hydrocortisone	substance	new	_	_
40-5	4362-4363	:	_	_	_	_
40-6	4364-4365	1	time[246]	new[246]	_	_
40-7	4366-4367	–	time[246]	new[246]	_	_
40-8	4368-4369	2	time[246]|quantity	new[246]|new	coref	40-19
40-9	4370-4379	mg/kg/day	_	_	_	_
40-10	4380-4381	)	_	_	_	_
40-11	4382-4385	and	_	_	_	_
40-12	4386-4399	antihistamine	abstract|person[249]	new|new[249]	_	_
40-13	4400-4406	agents	person[249]	new[249]	_	_
40-14	4407-4408	(	_	_	_	_
40-15	4409-4424	diphenhydramine	substance[250]	new[250]	_	_
40-16	4425-4426	:	substance[250]	new[250]	_	_
40-17	4427-4428	1	substance[250]	new[250]	_	_
40-18	4429-4430	–	substance[250]	new[250]	_	_
40-19	4431-4432	2	substance[250]|quantity	new[250]|giv	_	_
40-20	4433-4438	mg/kg	substance[250]|quantity	new[250]|new	_	_
40-21	4439-4440	)	_	_	_	_
40-22	4441-4444	are	_	_	_	_
40-23	4445-4451	useful	_	_	_	_
40-24	4452-4454	to	_	_	_	_
40-25	4455-4462	control	_	_	_	_
40-26	4463-4466	the	abstract[253]	giv[253]	_	_
40-27	4467-4475	allergic	abstract[253]	giv[253]	_	_
40-28	4476-4484	reaction	abstract[253]	giv[253]	_	_
40-29	4485-4486	.	_	_	_	_

#Text=Aspirin is , however , potentially detrimental because of cyclooxygenase inhibition , promoting arachidonic acid release into the leukotriene pathway .
41-1	4487-4494	Aspirin	substance	new	_	_
41-2	4495-4497	is	_	_	_	_
41-3	4498-4499	,	_	_	_	_
41-4	4500-4507	however	_	_	_	_
41-5	4508-4509	,	_	_	_	_
41-6	4510-4521	potentially	_	_	_	_
41-7	4522-4533	detrimental	_	_	_	_
41-8	4534-4541	because	_	_	_	_
41-9	4542-4544	of	_	_	_	_
41-10	4545-4559	cyclooxygenase	abstract|abstract[256]	new|new[256]	_	_
41-11	4560-4570	inhibition	abstract[256]	new[256]	_	_
41-12	4571-4572	,	_	_	_	_
41-13	4573-4582	promoting	_	_	_	_
41-14	4583-4594	arachidonic	abstract|event[259]	giv|new[259]	_	_
41-15	4595-4599	acid	substance|event[259]	giv|new[259]	coref	51-15[315_0]
41-16	4600-4607	release	event[259]	new[259]	_	_
41-17	4608-4612	into	_	_	_	_
41-18	4613-4616	the	abstract[261]	new[261]	_	_
41-19	4617-4628	leukotriene	abstract|abstract[261]	new|new[261]	_	_
41-20	4629-4636	pathway	abstract[261]	new[261]	_	_
41-21	4637-4638	.	_	_	_	_

#Text=Calcium channel blockers and nitrates can relieve the vasospasm .
42-1	4639-4646	Calcium	place|abstract[264]	new|new[264]	_	_
42-2	4647-4654	channel	place|abstract[264]	new|new[264]	_	_
42-3	4655-4663	blockers	abstract[264]	new[264]	_	_
42-4	4664-4667	and	_	_	_	_
42-5	4668-4676	nitrates	substance	new	coref	43-6
42-6	4677-4680	can	_	_	_	_
42-7	4681-4688	relieve	_	_	_	_
42-8	4689-4692	the	abstract[266]	giv[266]	coref	46-14[0_266]
42-9	4693-4702	vasospasm	abstract[266]	giv[266]	_	_
42-10	4703-4704	.	_	_	_	_

#Text=In hemodynamically unstable patients , nitrates may not be appropriate due to their hypotension properties .
43-1	4705-4707	In	_	_	_	_
43-2	4708-4723	hemodynamically	person[267]	giv[267]	ana	43-13[0_267]
43-3	4724-4732	unstable	person[267]	giv[267]	_	_
43-4	4733-4741	patients	person[267]	giv[267]	_	_
43-5	4742-4743	,	_	_	_	_
43-6	4744-4752	nitrates	substance	giv	_	_
43-7	4753-4756	may	_	_	_	_
43-8	4757-4760	not	_	_	_	_
43-9	4761-4763	be	_	_	_	_
43-10	4764-4775	appropriate	_	_	_	_
43-11	4776-4779	due	_	_	_	_
43-12	4780-4782	to	_	_	_	_
43-13	4783-4788	their	person|abstract[271]	giv|new[271]	coref|coref	50-2[306_0]|50-2[306_0]
43-14	4789-4800	hypotension	abstract|abstract[271]	new|new[271]	_	_
43-15	4801-4811	properties	abstract[271]	new[271]	_	_
43-16	4812-4813	.	_	_	_	_

#Text=Opioids may induce mast cell degeneration , which may worsen the anaphylaxis .
44-1	4814-4821	Opioids	substance	new	_	_
44-2	4822-4825	may	_	_	_	_
44-3	4826-4832	induce	_	_	_	_
44-4	4833-4837	mast	event[274]	new[274]	coref	46-8[284_274]
44-5	4838-4842	cell	place|event[274]	new|new[274]	coref	55-7
44-6	4843-4855	degeneration	event[274]	new[274]	_	_
44-7	4856-4857	,	_	_	_	_
44-8	4858-4863	which	_	_	_	_
44-9	4864-4867	may	_	_	_	_
44-10	4868-4874	worsen	_	_	_	_
44-11	4875-4878	the	abstract[275]	new[275]	_	_
44-12	4879-4890	anaphylaxis	abstract[275]	new[275]	_	_
44-13	4891-4892	.	_	_	_	_

#Text=Beta-blockers should be used with extreme caution because they can exaggerate coronary spasms and cause epinephrine to be ineffective .
45-1	4893-4906	Beta-blockers	abstract	new	ana	45-9
45-2	4907-4913	should	_	_	_	_
45-3	4914-4916	be	_	_	_	_
45-4	4917-4921	used	_	_	_	_
45-5	4922-4926	with	_	_	_	_
45-6	4927-4934	extreme	abstract[277]	new[277]	_	_
45-7	4935-4942	caution	abstract[277]	new[277]	_	_
45-8	4943-4950	because	_	_	_	_
45-9	4951-4955	they	abstract	giv	_	_
45-10	4956-4959	can	_	_	_	_
45-11	4960-4970	exaggerate	_	_	_	_
45-12	4971-4979	coronary	person|abstract[280]	giv|new[280]	_	_
45-13	4980-4986	spasms	abstract[280]	new[280]	_	_
45-14	4987-4990	and	_	_	_	_
45-15	4991-4996	cause	_	_	_	_
45-16	4997-5008	epinephrine	substance	new	coref	46-1
45-17	5009-5011	to	_	_	_	_
45-18	5012-5014	be	_	_	_	_
45-19	5015-5026	ineffective	_	_	_	_
45-20	5027-5028	.	_	_	_	_

#Text=Epinephrine is the only life-saving drug in the event of aggravated ischemia , vasospasm , and arrhythmias .
46-1	5029-5040	Epinephrine	substance	giv	coref	46-3[283_0]
46-2	5041-5043	is	_	_	_	_
46-3	5044-5047	the	substance[283]	giv[283]	_	_
46-4	5048-5052	only	substance[283]	giv[283]	_	_
46-5	5053-5064	life-saving	substance[283]	giv[283]	_	_
46-6	5065-5069	drug	substance[283]	giv[283]	_	_
46-7	5070-5072	in	substance[283]	giv[283]	_	_
46-8	5073-5076	the	substance[283]|event[284]	giv[283]|giv[284]	_	_
46-9	5077-5082	event	substance[283]|event[284]	giv[283]|giv[284]	_	_
46-10	5083-5085	of	substance[283]|event[284]	giv[283]|giv[284]	_	_
46-11	5086-5096	aggravated	substance[283]|event[284]|abstract[285]	giv[283]|giv[284]|new[285]	_	_
46-12	5097-5105	ischemia	substance[283]|event[284]|abstract[285]	giv[283]|giv[284]|new[285]	_	_
46-13	5106-5107	,	substance[283]|event[284]	giv[283]|giv[284]	_	_
46-14	5108-5117	vasospasm	substance[283]|event[284]|abstract	giv[283]|giv[284]|giv	_	_
46-15	5118-5119	,	substance[283]|event[284]	giv[283]|giv[284]	_	_
46-16	5120-5123	and	substance[283]|event[284]	giv[283]|giv[284]	_	_
46-17	5124-5135	arrhythmias	substance[283]|event[284]|abstract	giv[283]|giv[284]|new	_	_
46-18	5136-5137	.	_	_	_	_

#Text=In some animal studies , adrenaline may cause LV impairment and not recovery in established anaphylactic shock .
47-1	5138-5140	In	_	_	_	_
47-2	5141-5145	some	abstract[289]	new[289]	_	_
47-3	5146-5152	animal	animal|abstract[289]	new|new[289]	_	_
47-4	5153-5160	studies	abstract[289]	new[289]	_	_
47-5	5161-5162	,	_	_	_	_
47-6	5163-5173	adrenaline	substance	new	coref	48-3
47-7	5174-5177	may	_	_	_	_
47-8	5178-5183	cause	_	_	_	_
47-9	5184-5186	LV	object|abstract[292]	new|new[292]	_	_
47-10	5187-5197	impairment	abstract[292]	new[292]	_	_
47-11	5198-5201	and	_	_	_	_
47-12	5202-5205	not	_	_	_	_
47-13	5206-5214	recovery	event[293]	new[293]	_	_
47-14	5215-5217	in	event[293]	new[293]	_	_
47-15	5218-5229	established	event[293]|abstract[294]	new[293]|new[294]	_	_
47-16	5230-5242	anaphylactic	event[293]|abstract[294]	new[293]|new[294]	_	_
47-17	5243-5248	shock	event[293]|abstract[294]	new[293]|new[294]	_	_
47-18	5249-5250	.	_	_	_	_

#Text=Therefore , adrenaline is only suggested in high-grade anaphylactic reactions .
48-1	5251-5260	Therefore	_	_	_	_
48-2	5261-5262	,	_	_	_	_
48-3	5263-5273	adrenaline	substance	giv	_	_
48-4	5274-5276	is	_	_	_	_
48-5	5277-5281	only	_	_	_	_
48-6	5282-5291	suggested	_	_	_	_
48-7	5292-5294	in	_	_	_	_
48-8	5295-5305	high-grade	event[296]	new[296]	_	_
48-9	5306-5318	anaphylactic	event[296]	new[296]	_	_
48-10	5319-5328	reactions	event[296]	new[296]	_	_
48-11	5329-5330	.	_	_	_	_

#Text=Adequate fluids resuscitation and oxygen therapy are important supportive treatments for Kounis syndrome .
49-1	5331-5339	Adequate	abstract[298]	new[298]	_	_
49-2	5340-5346	fluids	substance|abstract[298]	new|new[298]	_	_
49-3	5347-5360	resuscitation	abstract[298]	new[298]	_	_
49-4	5361-5364	and	_	_	_	_
49-5	5365-5371	oxygen	substance|abstract[300]	new|new[300]	coref|coref	51-1[311_300]|51-1[311_300]
49-6	5372-5379	therapy	abstract[300]	new[300]	_	_
49-7	5380-5383	are	_	_	_	_
49-8	5384-5393	important	abstract[301]	giv[301]	_	_
49-9	5394-5404	supportive	abstract[301]	giv[301]	_	_
49-10	5405-5415	treatments	abstract[301]	giv[301]	_	_
49-11	5416-5419	for	abstract[301]	giv[301]	_	_
49-12	5420-5426	Kounis	abstract[301]|person|abstract[303]	giv[301]|giv|giv[303]	_	_
49-13	5427-5435	syndrome	abstract[301]|abstract[303]	giv[301]|giv[303]	_	_
49-14	5436-5437	.	_	_	_	_

#Text=Type II variant patients can take advantage of an ACS protocol .
50-1	5438-5442	Type	object	new	_	_
50-2	5443-5445	II	object[305]|person[306]	new[305]|giv[306]	coref|coref	52-4[321_305]|52-4[321_305]
50-3	5446-5453	variant	object[305]|person[306]	new[305]|giv[306]	_	_
50-4	5454-5462	patients	person[306]	giv[306]	_	_
50-5	5463-5466	can	_	_	_	_
50-6	5467-5471	take	_	_	_	_
50-7	5472-5481	advantage	abstract[307]	new[307]	_	_
50-8	5482-5484	of	abstract[307]	new[307]	_	_
50-9	5485-5487	an	abstract[307]|abstract[309]	new[307]|new[309]	coref	52-7[323_309]
50-10	5488-5491	ACS	abstract[307]|abstract|abstract[309]	new[307]|giv|new[309]	coref	52-8
50-11	5492-5500	protocol	abstract[307]|abstract[309]	new[307]|new[309]	_	_
50-12	5501-5502	.	_	_	_	_

#Text=Double antiplatelet therapy in the pharmacological treatment of myocardial revascularization is suggested , including acetylsalicylic acid ( ASA ) and another P2Y12 receptor inhibitor .
51-1	5503-5509	Double	abstract[311]	giv[311]	_	_
51-2	5510-5522	antiplatelet	abstract|abstract[311]	new|giv[311]	_	_
51-3	5523-5530	therapy	abstract[311]	giv[311]	_	_
51-4	5531-5533	in	abstract[311]	giv[311]	_	_
51-5	5534-5537	the	abstract[311]|abstract[312]	giv[311]|new[312]	_	_
51-6	5538-5553	pharmacological	abstract[311]|abstract[312]	giv[311]|new[312]	_	_
51-7	5554-5563	treatment	abstract[311]|abstract[312]	giv[311]|new[312]	_	_
51-8	5564-5566	of	abstract[311]|abstract[312]	giv[311]|new[312]	_	_
51-9	5567-5577	myocardial	abstract[311]|abstract[312]|event[313]	giv[311]|new[312]|new[313]	coref	55-19[0_313]
51-10	5578-5595	revascularization	abstract[311]|abstract[312]|event[313]	giv[311]|new[312]|new[313]	_	_
51-11	5596-5598	is	_	_	_	_
51-12	5599-5608	suggested	_	_	_	_
51-13	5609-5610	,	_	_	_	_
51-14	5611-5620	including	_	_	_	_
51-15	5621-5636	acetylsalicylic	person|abstract[315]	new|giv[315]	appos|appos	51-18[0_315]|51-18[0_315]
51-16	5637-5641	acid	abstract[315]	giv[315]	_	_
51-17	5642-5643	(	_	_	_	_
51-18	5644-5647	ASA	abstract	giv	_	_
51-19	5648-5649	)	_	_	_	_
51-20	5650-5653	and	_	_	_	_
51-21	5654-5661	another	abstract[319]	new[319]	_	_
51-22	5662-5667	P2Y12	abstract|abstract[319]	new|new[319]	_	_
51-23	5668-5676	receptor	substance|abstract[319]	new|new[319]	_	_
51-24	5677-5686	inhibitor	abstract[319]	new[319]	_	_
51-25	5687-5688	.	_	_	_	_

#Text=In the type III variant , the ACS protocol accompanied by urgent aspiration of intrastent thrombus is suggested (
52-1	5689-5691	In	_	_	_	_
52-2	5692-5695	the	abstract[320]	new[320]	_	_
52-3	5696-5700	type	abstract[320]	new[320]	_	_
52-4	5701-5704	III	object[321]	giv[321]	_	_
52-5	5705-5712	variant	object[321]	giv[321]	_	_
52-6	5713-5714	,	_	_	_	_
52-7	5715-5718	the	abstract[323]	giv[323]	_	_
52-8	5719-5722	ACS	abstract|abstract[323]	giv|giv[323]	_	_
52-9	5723-5731	protocol	abstract[323]	giv[323]	_	_
52-10	5732-5743	accompanied	_	_	_	_
52-11	5744-5746	by	_	_	_	_
52-12	5747-5753	urgent	event[324]	new[324]	_	_
52-13	5754-5764	aspiration	event[324]	new[324]	_	_
52-14	5765-5767	of	event[324]	new[324]	_	_
52-15	5768-5778	intrastent	event[324]|abstract[325]	new[324]|new[325]	_	_
52-16	5779-5787	thrombus	event[324]|abstract[325]	new[324]|new[325]	_	_
52-17	5788-5790	is	_	_	_	_
52-18	5791-5800	suggested	_	_	_	_
52-19	5801-5802	(	_	_	_	_

#Text=Figure 5
53-1	5803-5809	Figure	abstract[326]	giv[326]	_	_
53-2	5810-5811	5	abstract[326]	giv[326]	_	_

#Text=) .
54-1	5812-5813	)	_	_	_	_
54-2	5814-5815	.	_	_	_	_

#Text=Antihistamines , corticosteroids , and mast cell stabilizers may be helpful for allergic symptoms after stent implantation or revascularization .
55-1	5816-5830	Antihistamines	substance	new	_	_
55-2	5831-5832	,	_	_	_	_
55-3	5833-5848	corticosteroids	object	giv	_	_
55-4	5849-5850	,	_	_	_	_
55-5	5851-5854	and	_	_	_	_
55-6	5855-5859	mast	object[330]	new[330]	_	_
55-7	5860-5864	cell	place|object[330]	giv|new[330]	_	_
55-8	5865-5876	stabilizers	object[330]	new[330]	_	_
55-9	5877-5880	may	_	_	_	_
55-10	5881-5883	be	_	_	_	_
55-11	5884-5891	helpful	_	_	_	_
55-12	5892-5895	for	_	_	_	_
55-13	5896-5904	allergic	abstract[331]	new[331]	_	_
55-14	5905-5913	symptoms	abstract[331]	new[331]	_	_
55-15	5914-5919	after	abstract[331]	new[331]	_	_
55-16	5920-5925	stent	abstract[331]|abstract|event[333]	new[331]|new|new[333]	_	_
55-17	5926-5938	implantation	abstract[331]|event[333]	new[331]|new[333]	_	_
55-18	5939-5941	or	abstract[331]	new[331]	_	_
55-19	5942-5959	revascularization	abstract[331]|event	new[331]|giv	_	_
55-20	5960-5961	.	_	_	_	_
